U.S. Securities and Exchange Commission

The9 Limited to Hold Annual General Meeting on December 19, 2022

Retrieved on: 
Thursday, November 17, 2022

SHANGHAI, Nov. 17, 2022 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) (the "Company"), an established Internet company, today announced that it will hold its annual general meeting of shareholders ("AGM") at the Company's business office, 17 Floor, No.

Key Points: 
  • SHANGHAI, Nov. 17, 2022 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) (the "Company"), an established Internet company, today announced that it will hold its annual general meeting of shareholders ("AGM") at the Company's business office, 17 Floor, No.
  • The Company's Annual Report can be accessed on the investor relations section of its website at http://www.the9.com , and on the SEC's website at http://www.sec.gov .
  • Holders of the Company's ordinary shares or ADSs may obtain a copy of the Company's Annual Report, free of charge, by email to [email protected] or by writing to:
    The9 Limited (The9) is an Internet company listed on Nasdaq in 2004.
  • The9 aims to become a global diversified high-tech Internet company, and is engaged in blockchain business including the operation of cryptocurrency mining and a Non-Fungible Token platform NFTSTAR.

Elbit Systems Awarded a $200 Million Contract to Supply Helicopter Self-Protection Suits to a Country in Asia-Pacific

Retrieved on: 
Thursday, November 17, 2022

Forward-looking statements are based on management's current expectations, estimates, projections and assumptions about future events.

Key Points: 
  • Forward-looking statements are based on management's current expectations, estimates, projections and assumptions about future events.
  • Forwardlooking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.
  • Elbit Systems Ltd., its logo, brand, product, service and process names appearing in this Press Release are the trademarks or service marks of Elbit Systems Ltd. or its affiliated companies.
  • Reference to or use of a product, service or process other than those of Elbit Systems Ltd. does not imply recommendation, approval, affiliation or sponsorship of that product, service or process by Elbit Systems Ltd.

NetEase Announces Non-Renewal of Licenses with Blizzard

Retrieved on: 
Thursday, November 17, 2022

We will make sure our players' data and assets are well protected in all of our games," said William Ding, CEO of NetEase.

Key Points: 
  • We will make sure our players' data and assets are well protected in all of our games," said William Ding, CEO of NetEase.
  • As a leading internet technology company based in China, NetEase, Inc. (NASDAQ: NTES and HKEX:9999, "NetEase") provides premium online services centered around content creation.
  • By infusing play with culture and education with technology, NetEase transforms gaming into a meaningful vehicle to build a more entertaining and enlightened world.
  • NetEase does not undertake any obligation to update this forward-looking information, except as required under the applicable law.

Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

Retrieved on: 
Wednesday, November 16, 2022

WALTHAM, Mass., Nov. 16, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced the vote of the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting for XPHOZAH for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. The CRDAC voted nine to four that the benefits of treatment with XPHOZAH outweigh its risks for the control of serum phosphorus in adults with CKD on dialysis when administered as a monotherapy and voted ten to two, with one abstention, that the benefits of treatment with XPHOZAH in combination with phosphate binder treatment outweigh its risks.

Key Points: 
  • "We are confident that the data from three Phase 3 clinical trials involving more than 1,200 patients support the approval of XPHOZAH in the U.S. for the control of serum phosphorus in adult patients with CKD on dialysis.
  • We want to thank the patients, physicians and the advocacy community who shared their valuable insights today and throughout the development program.
  • The nephrology community is enthusiastic to have access to this therapy with its novel mechanism of action to help our patients."
  • Ardelyx is developing XPHOZAH (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials.

OpenText Announces Pricing of Notes Offering and Successful Term Loan Syndication as part of Micro Focus Acquisition Financing

Retrieved on: 
Wednesday, November 16, 2022

The Notes Offering is expected to close, and the Term Loan credit agreement is expected to be amended, on December 1, 2022, subject in each case to customary conditions.

Key Points: 
  • The Notes Offering is expected to close, and the Term Loan credit agreement is expected to be amended, on December 1, 2022, subject in each case to customary conditions.
  • The net proceeds from the Notes Offering, borrowings under the Term Loan and the Company's existing revolving credit facility, and cash on hand will be used to fund the Acquisition.
  • As previously announced, shareholders of Micro Focus have approved the terms of the Acquisition.
  • The Acquisition is expected to close in the first calendar quarter of 2023, subject to regulatory approvals and customary closing conditions.

CENTENE APPOINTS MONTE FORD TO BOARD OF DIRECTORS

Retrieved on: 
Wednesday, November 16, 2022

ST. LOUIS, Nov. 16, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today that it has appointed Monte Ford to the Centene Board of Directors, effective November 12th.

Key Points: 
  • ST. LOUIS, Nov. 16, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today that it has appointed Monte Ford to the Centene Board of Directors, effective November 12th.
  • Mr. Ford is a leading technologist with more than 20 years of board experience serving Fortune 500 companies across a wide spectrum of industries.
  • "Monte's extensive experience in the Fortune 500 technology sector will serve Centene well as we continue to use data to drive innovation and transform healthcare for our members," said James Dallas,Chairman of the Centene Board of Directors.
  • "I look forward to working with Centene, a company with which I share a vision of transforming healthcare through innovative technology and programs," said Ford.

Kulicke & Soffa Reports Fourth Quarter 2022 Results

Retrieved on: 
Wednesday, November 16, 2022

Through organic development, prudent acquisitions and close industry partnerships, Kulicke & Soffa's served available market has grown to approximately $4.7 billion in fiscal 2022, up 51 percent from fiscal 2018.

Key Points: 
  • Through organic development, prudent acquisitions and close industry partnerships, Kulicke & Soffa's served available market has grown to approximately $4.7 billion in fiscal 2022, up 51 percent from fiscal 2018.
  • Repurchased approximately 5.6 million shares of common stock through open market and accelerated programs at a cost of $282.8 million.
  • A conference call to discuss these results will be held tomorrow,November 17, 2022, beginning at8:00am EST.
  • Management uses both U.S. GAAP metrics as well as non-GAAP metrics to evaluate the Company's operating and financial results.

INX Reports Q3 2022 Cumulative Adjusted Operating Cash Flow and Pro Rata Portion of the Distributable Amount per INX Token

Retrieved on: 
Wednesday, November 16, 2022

The distribution to holders of the INX Tokens will be based on a final calculation of our cumulative Adjusted Operating Cash Flow and the pro rata portion of the Distributable Amount per INX Token.

Key Points: 
  • The distribution to holders of the INX Tokens will be based on a final calculation of our cumulative Adjusted Operating Cash Flow and the pro rata portion of the Distributable Amount per INX Token.
  • The distribution to INX Token Holders is a contractual obligation of the Company and a right of each INX Token holder of record as of March 31 of a year following a year end for which there was positive cumulative Adjusted Operating Cash Flow.
  • However, the pro rata distribution of our cumulative Adjusted Operating Cash Flow is not self-executing and requires that our board of directors approve the Company's financial statements and calculate such distribution in good faith.
  • Further, although the annual calculation of our cumulative Adjusted Operating Cash Flow will be based on information provided in the audited consolidated financial statements of INX Limited and its subsidiaries, neither the calculation of the cumulative Adjusted Operating Cash Flow nor any pro rata distributions thereof to token holders will be audited at the time of any distribution.

INX Reports Q3 2022 Cumulative Adjusted Operating Cash Flow and Pro Rata Portion of the Distributable Amount per INX Token

Retrieved on: 
Wednesday, November 16, 2022

The distribution to holders of the INX Tokens will be based on a final calculation of our cumulative Adjusted Operating Cash Flow and the pro rata portion of the Distributable Amount per INX Token.

Key Points: 
  • The distribution to holders of the INX Tokens will be based on a final calculation of our cumulative Adjusted Operating Cash Flow and the pro rata portion of the Distributable Amount per INX Token.
  • The distribution to INX Token Holders is a contractual obligation of the Company and a right of each INX Token holder of record as of March 31 of a year following a year end for which there was positive cumulative Adjusted Operating Cash Flow.
  • However, the pro rata distribution of our cumulative Adjusted Operating Cash Flow is not self-executing and requires that our board of directors approve the Company's financial statements and calculate such distribution in good faith.
  • Further, although the annual calculation of our cumulative Adjusted Operating Cash Flow will be based on information provided in the audited consolidated financial statements of INX Limited and its subsidiaries, neither the calculation of the cumulative Adjusted Operating Cash Flow nor any pro rata distributions thereof to token holders will be audited at the time of any distribution.